Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Vysis

This article was originally published in The Gray Sheet

Executive Summary

Vysis: Initial public offering Feb. 5 nets about $33.5 mil. The genetic test and disease management firm's IPO consisted of 3 mil. shares of common stock at $12 per share. Initial plans for the offering, announced in October, called for a slightly larger offering of 3.5 mil. shares ("The Gray Sheet" Nov. 3, I&W-5). The Downers Grove, Illinois-based firm plans to use a portion of the proceeds for expansion of direct sales and marketing capabilities. Underwriters Furman Selz, Deutsche Morgan Grenfell and Everen Securities hold an overallotment option for up to 450,000 additional shares...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009584

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel